MinhTri Nguyen, MD

@minhtrimd.bsky.social

Medical Oncologist at Stanford | Certified Coach | Researcher in emotional intelligence | Always learning, and finding good food. My opinions are my own. #Medsky #Oncosky

No generational judgement—disheartening to see burnout at all. Especially in In a field that clearly still holds joy for those that practice. The landscape is not what it used to be & we’ve trained to be nimble with medical decision—not staffing, prior auth, or EMR burden.

Jame Abraham, MD, FACP@jameabraham.bsky.social · 2y ago

Trends in Well-Being and Burnout Among U.S. Oncologists: Challenges and Solutions @ascocancer.bsky.social @acochran12733.bsky.social @jrgralow.bsky.social ascopubs.org/doi/10.1200/... @oncoalert.bsky.social

I was born in the mountains of 🇻🇳. At 5 my parents sought the land of opportunity 🇺🇸. This Dec our family reunited in 🇻🇳. My country has changed and so have we. Change = opportunity. From my Fam to yours: Happy new years! With the change, I hope you also find your opportunities to grow.

Bild

A bit late on the announcement but thrilled to be selected for the Stanford Physician Leadership Certificate Program! I look forward to learning and enhancing my leadership skills and leadership theory. I accept! (-ed before the deadline) :) #leadership

Bild

The selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs. 5.5 months with imlunestrant alone). Full EMBER-3 trial results: nej.md/4fZ74HX #MedSky #SABCS24

Kaplan–Meier estimates of progression-free survival among all 426 patients in the imlunestrant–abemaciclib and imlunestrant groups who had undergone randomization concurrently.

I’ve found many apps to be extremely useful as a fellow and practicing oncologist. For a quick (usually less than 48 hrs) curbside consult to an Oncologist, Hematologist, RadOnc, Pharmacist etc. I’ve been using Primum. You can also ask anonymously. See link. #oncsky #cansky #medsky

Primum

A digital platform helping patients receive better care closer to home. We connect oncologists with sub-specialists to discuss their most complex cancer cases.

app.primum.co

We have known for decade+ that you can detect progression using ctDNA months before you see it on scans. But until we show that it impacts outcomes to change tx earlier all it does is make ppl anxious and abandon treatments (TKIs) that may still be helping. Most MRD use today is marketing over data.

Laura Book@laurajbook.bsky.social · 2y ago

Why aren’t more oncologists using MRD tests like Signatera or Guardant Reveal to proactively treat NSCLC before PD shows up on imaging especially in later treatment lines? www.jto.org/article/S155...

Amazing. Imagine the next level: Incorporating such large language models into our EMR systems to provide suggested matched clinical trials in real time! These LLM are already being trialed and implemented for inbox management at some institutions. Anxiously hopeful. 🙏

Jarushka Naidoo@drjnaidoo.bsky.social · 2y ago

'TrialGPT' A new chatGPT for clinical trials @natureportfolio.bsky.social: - 3 steps: TrialGPT-Retrieval, TrialGPT-Matching, TrialGPT-Ranking - Retrieval identified 90% suitable trials - 42% time-saving in matching a patient to a trial Like, wow #MedSky #OncSky #LCSM www.nature.com/articles/s41...